HUN Stock Analysis: Huntsman | NYSE

Chemicals | NYSE, USA | Market Cap: 2.117m USD | 12M Return: 5.1% | Charts, Fundamentals & Technical Analysis

Polyurethanes, Amines, Epoxy Resins, Catalysts
Total Rating 25
Safety 61
Buy Signal -1.50
Chemicals
Industry Rotation: +16.3
Market Cap: 2.12B
Avg Turnover: 44.3M
Risk 3d forecast
Volatility85.2%
VaR 5th Pctl14.4%
VaR vs Median6.96%
Reward TTM
Sharpe Ratio0.32
Rel. Str. IBD14
Rel. Str. Peer Group5.6
Character TTM
Beta1.139
Beta Downside1.318
Hurst Exponent0.452
Drawdowns 3y
Max DD70.77%
CAGR/Max DD-0.38
CAGR/Mean DD-0.78
EPS (Earnings per Share) EPS (Earnings per Share) of HUN over the last years for every Quarter: "2021-06": 0.86, "2021-09": 1.08, "2021-12": 0.95, "2022-03": 1.19, "2022-06": 1.28, "2022-09": 0.71, "2022-12": 0.04, "2023-03": 0.2, "2023-06": 0.22, "2023-09": 0.15, "2023-12": -0.21, "2024-03": -0.06, "2024-06": 0.14, "2024-09": -0.1917, "2024-12": -0.25, "2025-03": -0.11, "2025-06": -0.2, "2025-09": -0.03, "2025-12": -0.37, "2026-03": -0.2, "2026-06": -0.2,
Last SUE: -2.16
Qual. Beats: -1
Revenue Revenue of HUN over the last years for every Quarter: 2021-06: 2024, 2021-09: 2097, 2021-12: 2307, 2022-03: 2192, 2022-06: 2170, 2022-09: 2011, 2022-12: 1650, 2023-03: 1606, 2023-06: 1596, 2023-09: 1506, 2023-12: 1403, 2024-03: 1470, 2024-06: 1574, 2024-09: 1540, 2024-12: 1452, 2025-03: 1410, 2025-06: 1458, 2025-09: 1460, 2025-12: 1355, 2026-03: 1420, 2026-06: null,
Rev. CAGR: -4.82%
Rev. Trend: -86.1%
Last SUE: 0.89
Qual. Beats: 1

Warnings

High Debt/EBITDA With Thin Interest Coverage
Interest Coverage Ratio Critical
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan +1.2% 39
Feb +4.2% 17
Mar -1.1% 0
Apr -2.4% 27
May -1.8% 0
Jun -3.9% 15
Jul +1.9% 6
Aug -3.6% 26
Sep -0.2% 8
Oct -1.1% 8
Nov -0.5% 5
Dec +2.9% 23

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: HUN Huntsman

Huntsman Corporation (NYSE: HUN) is a global manufacturer of diversified organic chemical products operating through three segments: Polyurethanes, Performance Products, and Advanced Materials. Founded in 1970 and headquartered in The Woodlands, Texas, the company went public in February 2005 and is classified within the GICS Materials sector under the Diversified Chemicals sub-industry, with a mid-cap market capitalization of approximately $2.1 billion.

The Polyurethanes segment produces MDI, polyols, thermoplastic polyurethane, and related co-products such as aniline and benzene. The Performance Products segment focuses on amines and catalysts, while the Advanced Materials segment supplies epoxy, phenoxy, acrylic, polyurethane, and acrylonitrile-butadiene-based polymer formulations. Together, the portfolio serves a broad set of end markets, including automotive, aerospace, construction, electronics, packaging, oil and gas, footwear, furniture, power generation, and medical appliances. Huntsman distributes its products globally through a network of third-party distributors and agents, supplementing this with pre- and post-sales technical service support for customers.

As a diversified chemicals producer, Huntsmans revenue and margins are typically exposed to the cyclical pricing of commodity feedstocks and downstream chemical demand, particularly within housing, automotive, and industrial end markets. The companys segment structure reflects a balance between higher-volume polyurethane commodity chemicals and higher-margin specialty formulations used in adhesives, coatings, and electronics.

Headlines to Watch Out For
  • MDI oversupply pressures polyurethane selling prices globally
  • Aerospace recovery boosts Advanced Materials volumes and margins
  • European industrial demand softness weighs on overall volumes
Piotroski VR-10 (Strict) 2.0
Net Income: -324.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.84 > 1.0
NWC/Revenue: 5.46% < 20% (prev 12.48%; Δ -7.02% < -1%)
CFO/TA 0.04 > 3% & CFO 310.0m > Net Income -324.0m
Net Debt (2.55b) to EBITDA (124.0m): 20.56 < 3
Current Ratio: 1.18 > 1.5 & < 3
Outstanding Shares: last quarter (173.0m) vs 12m ago 0.35% < -2%
Gross Margin: 12.88% > 18% (prev 14.49%; Δ -1.62% > 0.5%)
Asset Turnover: 79.27% > 50% (prev 82.63%; Δ -3.36% > 0%)
Interest Coverage Ratio: -2.06 > 6 (EBIT TTM -167.0m / Interest Expense TTM 81.0m)
Altman Z'' 1.59
A: 0.04 (Total Current Assets 2.03b - Total Current Liabilities 1.72b) / Total Assets 7.13b
B: 0.24 (Retained Earnings 1.74b / Total Assets 7.13b)
C: -0.02 (EBIT TTM -167.0m / Avg Total Assets 7.18b)
D: 0.63 (Book Value of Equity 2.68b / Total Liabilities 4.23b)
Altman-Z'' = 1.59 = BB
Beneish M -2.76
DSRI: 1.02 (Receivables 776.0m/797.0m, Revenue 5.69b/5.98b)
GMI: 1.13 (GM 14.49% / 12.88%)
AQI: 1.30 (AQ_t 0.37 / AQ_t-1 0.29)
SGI: 0.95 (Revenue 5.69b / 5.98b)
TATA: -0.09 (NI -324.0m - CFO 310.0m) / TA 7.13b)
Beneish M = -2.76 (Cap -4..+1) = A
What is the price of HUN shares?

As of August 02, 2026, the stock is trading at USD 9.76 with a total of 8,149,134 shares traded. Over the past week, the price has changed by -23.75%, over one month by -8.10%, over three months by -31.70% and over the past year by +5.14%.

Current recommended Stop Loss: 8.90 (which is 8.8% or 1.4 ATR below the current price).

Is HUN a buy, sell or hold?

Huntsman has received a consensus analysts rating of 3.13. Therefore, it is recommended to hold HUN.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 12
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the HUN price?
Analysts Target Price 13.6 39.1%
Huntsman (HUN) - Fundamental Data Overview as of 02 August 2026
Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/E Forward = 153.8462
P/S = 0.3718
P/B = 0.7824
P/EG = 2.2202
Revenue TTM = 5.69b USD
EBIT TTM = -167.0m USD
EBITDA TTM = 124.0m USD
Long Term Debt = 1.68b USD (from longTermDebt, last quarter)
Short Term Debt = 433.0m USD (from shortTermDebt, last quarter)
Debt = 2.92b USD (from shortLongTermDebtTotal, last quarter) + Leases 431.0m
Net Debt = 2.55b USD (calculated: Debt 2.92b - CCE 369.0m)
Enterprise Value = 4.67b USD (2.12b + Debt 2.92b - CCE 369.0m)
Interest Coverage Ratio = -2.06 (Ebit TTM -167.0m / Interest Expense TTM 81.0m)
EV/FCF = 34.56x (Enterprise Value 4.67b / FCF TTM 135.0m)
FCF Yield = 2.89% (FCF TTM 135.0m / Enterprise Value 4.67b)
FCF Margin = 2.37% (FCF TTM 135.0m / Revenue TTM 5.69b)
Net Margin = -5.69% (Net Income TTM -324.0m / Revenue TTM 5.69b)
Gross Margin = 12.88% ((Revenue TTM 5.69b - Cost of Revenue TTM 4.96b) / Revenue TTM)
Gross Margin QoQ = 12.89% (prev 12.10%)
Tobins Q-Ratio = 0.65 (Enterprise Value 4.67b / Total Assets 7.13b)
Interest Expense / Debt = 2.78% (Interest Expense 81.0m / Debt 2.92b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -131.9m (EBIT -167.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.18 (Total Current Assets 2.03b / Total Current Liabilities 1.72b)
Debt / Equity = 1.09 (Debt 2.92b / totalStockholderEquity, last quarter 2.68b)
Debt / EBITDA = 20.56 (Net Debt 2.55b / EBITDA 124.0m)
Debt / FCF = 18.88 (Net Debt 2.55b / FCF TTM 135.0m)
Total Stockholder Equity = 2.76b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.51% (Net Income -324.0m / Total Assets 7.13b)
RoE = -11.76% (Net Income TTM -324.0m / Total Stockholder Equity 2.76b)
RoCE = -3.76% (EBIT -167.0m / Capital Employed (Equity 2.76b + L.T.Debt 1.68b))
 RoIC = -2.37% (negative operating profit) (NOPAT -131.9m / Invested Capital 5.56b)
 WACC = 5.47% (E(2.12b)/V(5.03b) * Re(9.99%) + D(2.92b)/V(5.03b) * Rd(2.78%) * (1-Tc(0.21)))
Discount Rate = 9.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.12 | Cagr: 0.26%
[DCF] Terminal Value 77.97% ; FCFF base≈111.4m ; Y1≈127.7m ; Y5≈187.9m
[DCF] Fair Price = 1.59 (EV 2.83b - Net Debt 2.55b = Equity 279.2m / Shares 175.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.16 | # QB: -1
Revenue Correlation: -86.06 | Revenue CAGR: -4.82% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=-6.98% | Revisions=+25% | Analysts=12
EPS current Year (2026-12-31): EPS=-0.18 | Chg30d=+1.66% | Revisions=+25% | GrowthEPS=+73.7% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=0.19 | Chg30d=-11.16% | Revisions=+0% | GrowthEPS=+203.0% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +40% (up=2, down=0)